clinical trial designs and one that is long, expensive, devilishly tricky to execute, and not certain to be acceptable to regulatory authorities for providing a disease-modifying indication even if positive. The intention of our article was to provide an easier pathway for developing putative disease-modifying treatments that could provide meaningful benefits to PD patients at a time when many major pharmaceutical companies are abandoning the field because of the costs, risks, and uncertainties of current approaches aimed at providing a "disease-modifying" indication. We believe that studies using the delayed-start design are laudable and could still be pursued in an attempt to obtain a "disease-modifying" indication, but suggest an alternate approach that avoids delaying the introduction of new therapies that improve function and slow progression of disability for PD patients.